Loading organizations...
§ Private Profile · Cambridge, MA, USA
Glympse Bio is a company.
Glympse Bio has raised $76.0M across 3 funding rounds.
Key people at Glympse Bio.
Glympse Bio has raised $76.0M in total across 3 funding rounds.
Glympse Bio develops a diagnostic platform utilizing proprietary injectable nanoparticles to detect and quantify disease-specific protease activity. These nanoparticles generate signals analyzed in urine, offering a noninvasive method for real-time disease monitoring. The technology provides detailed insights into disease states, initially focusing on Non-Alcoholic Steatohepatitis.
The company originated in 2016 as a spinout from the Massachusetts Institute of Technology. Its foundation stems from a 2013 project on ultrasensitive noninvasive disease monitoring, pioneered by Professor Sangeeta Bhatia's laboratory. The key insight involved leveraging protease activity as a powerful biomarker, enabling precise understanding of disease progression.
Glympse Bio aims to empower healthcare providers with tools for earlier detection and more effective, noninvasive disease monitoring. The platform envisions establishing a new diagnostic paradigm, delivering continuous, high-resolution data on disease activity. This approach seeks to improve patient outcomes through timely and targeted therapeutic interventions.
Glympse Bio has raised $76.0M across 3 funding rounds. Most recently, it raised $47.0M Series B in July 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2020 | $47M Series B | Section 32 | Acrew Capital, CRV, GreatPoint Ventures, OrbiMed, Polaris Partners, SV Health Investors, ARCH Venture Partners, Catalio Capital, DNS Capital, Gilead Sciences, LS Polaris Innovation Fund, NEW Leaf Venture Partners, Cayce Denton, Waterman Ventures | Announced |
| Oct 1, 2018 | $22M Series A | ARCH Venture Partners, AMY Schulman | Acrew Capital, CRV, GreatPoint Ventures, OrbiMed, Polaris Partners, Section 32, SV Health Investors, Gilead Sciences, Heritage Provider Network, Inevitable Ventures, Rivas Capital, Yonghua Capital | Announced |
| Nov 1, 2015 | $7M Seed | — | Accel, Acrew Capital, Brand Foundry Ventures, Forerunner Ventures, Grace Beauty Capital, Harrison Metal, Lerer Hippeau, Offline Ventures, Slow Ventures, The General Partnership, Vayner RSE | Announced |
Key people at Glympse Bio.
Glympse Bio has raised $76.0M in total across 3 funding rounds.
Glympse Bio's investors include Section 32, Acrew Capital, CRV, GreatPoint Ventures, OrbiMed, Polaris Partners, SV Health Investors, ARCH Venture Partners, Catalio Capital Management, DNS Capital, Gilead Sciences, LS Polaris Innovation Fund.
Glympse Bio is a biotechnology company that develops a novel, tunable biosensor platform for noninvasive and predictive monitoring of multiple human diseases. Its core product leverages engineered diagnostic agents to measure the activity of specific proteases—enzymes critical to cellular function and disease progression—directly in the body. This approach aims to provide more accurate and dynamic disease insights compared to traditional RNA-based diagnostics. Glympse Bio primarily serves biopharma companies and researchers by enabling earlier and more precise disease detection, which can improve patient outcomes and accelerate drug development. The company has demonstrated growth momentum through successful funding rounds, including a Series B raising over $95 million, and strategic moves such as merging with Sunbird Bio to accelerate its protein-based diagnostic technology[1][2][3][4].
Founded in 2015 and headquartered in Cambridge, Massachusetts, Glympse Bio was established to address limitations in existing diagnostic methods by focusing on protease activity as a biomarker. The founders, with backgrounds in biotechnology and molecular biology, recognized that proteases—of which there are 566 types in humans—play a fundamental role in disease mechanisms and could provide unique diagnostic insights. Early pivotal moments include preclinical studies demonstrating the platform’s ability to differentiate hepatocellular carcinoma patients from healthy controls, validating the concept and attracting investment and partnerships. The merger with Sunbird Bio further marked a key evolution in accelerating the development and commercialization of their diagnostic platform[1][3][4].
Glympse Bio rides the growing trend of precision medicine and noninvasive diagnostics, where real-time, functional biomarkers are increasingly valued for their ability to improve disease detection and monitoring. The timing is favorable due to advances in biotechnology, increasing demand for early disease detection, and the pharmaceutical industry's need for better diagnostic tools to guide drug development. By focusing on protease activity, Glympse Bio taps into a relatively underexplored biomarker space with high potential impact. Its technology influences the broader ecosystem by enabling more personalized healthcare and fostering collaborations that bridge biotech innovation with clinical application[1][2][4].
Looking ahead, Glympse Bio is positioned to expand its diagnostic platform’s applications across a wider range of diseases, potentially transforming how conditions are detected and monitored. Trends such as the rise of liquid biopsies, AI-driven biomarker analysis, and personalized medicine will likely shape its journey. Continued partnerships and further clinical validation will be critical to scaling its impact. As the company matures, it may also influence regulatory standards and diagnostic paradigms, reinforcing its role as a pioneer in protease-based diagnostics. This trajectory ties back to its founding vision of revolutionizing disease monitoring through innovative biosensor technology[1][2][3][4].
